Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XBiotech Inc (NASDAQ: XBIT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. XBiotech is a British Columbia, Canada corporation with headquarters in Austin, Texas, and it uses its SEC reports to communicate material information about governance, executive compensation, shareholder votes and other corporate matters related to its True Human™ antibody business.
Through current reports on Form 8‑K, XBiotech has disclosed events such as the appointment of new members to its board of directors and their roles on the Audit and Compensation Committees, as well as the terms of an executive employment agreement that outlines compensation and severance arrangements for a senior leader. Other 8‑K filings describe material agreements and provide context on how the company structures leadership transitions and board oversight.
The company’s definitive proxy statement on Schedule 14A details items presented at its annual meeting of shareholders, including the election of directors, ratification of its independent registered public accounting firm, advisory votes on executive compensation and approval of an equity incentive plan. The proxy materials also explain voting procedures, record dates and how shareholders can participate in the virtual annual meeting format.
On Stock Titan, these filings are available alongside AI‑powered summaries that highlight key points from lengthy documents such as proxy statements and 8‑K exhibits. Users can review vote results, committee composition, and compensation structures, and can track how XBiotech’s governance and corporate policies evolve over time. Real‑time updates from EDGAR, combined with AI explanations, help readers quickly understand the implications of new filings without having to parse every page of the underlying documents.
XBiotech Inc. reported Q3 2025 results, posting a net loss of $6.0 million as operating expenses fell with no active clinical trials. Cash and cash equivalents were $147.4 million at September 30, 2025, supporting ongoing R&D and facility plans.
Research and development expense was $5.1 million in Q3 (down from $7.1 million), mainly from lower clinical and manufacturing activity. General and administrative expense was $1.0 million. Other income reflected $1.4 million of interest income and a $1.2 million foreign exchange loss. For the nine months, net loss was $18.6 million.
The company repaid in full a $10 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. On October 2, 2025, XBiotech entered a new executive employment agreement with its CEO, providing a $1,250,000 base salary, eligibility for a $4,530,442 base bonus, and severance equal to three years of base salary and base bonus upon certain separations. Shares outstanding were 30,487,731 as of November 12, 2025.
XBiotech Inc. (XBIT) reported a Form 4 for director Craig Rademaker. On October 1, 2025, he received a nonstatutory stock option grant for 92,104 options with an exercise price of $2.64 per share under the company’s 2025 Equity Incentive Plan. The options relate to common stock and were acquired at no cost.
The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year term expiring on October 1, 2035. Following the transaction, 92,104 derivative securities are beneficially owned directly.
XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share. The award was granted on October 1, 2025 under the company’s 2025 Equity Incentive Plan. According to the filing, the options vest in two equal portions at four months and ten months from the grant date and carry a ten-year term, expiring on October 1, 2035. Following the grant, 51,000 derivative securities are beneficially owned, held directly.
XBiotech (XBIT) reported a director equity grant. On October 1, 2025, the reporting person received 79,115 nonstatutory stock options to purchase common stock at an exercise price of $2.64, equal to the closing sale price on the grant date. The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year expiration. The filing lists the holder’s relationship as Director and shows direct (D) ownership.
XBiotech Inc. filed a Form 4 reporting a director stock option grant. On October 1, 2025, the reporting person received 56,000 nonstatutory options with a per‑share exercise price of $2.64 under the company’s 2025 Equity Incentive Plan.
The options vest in two equal portions at four months and ten months from the grant date and expire on October 1, 2035. Following the transaction, 56,000 derivative securities were beneficially owned directly.
XBiotech Inc. has entered into a new Executive Employment Agreement with its CEO and President, John Simard, effective October 1, 2025, replacing all prior arrangements. The agreement, approved by the Compensation Committee of independent directors, formalizes his pay structure and is intended to recognize his past and ongoing contributions and support leadership continuity and any future transition.
Under the agreement, Mr. Simard’s annual base salary remains at USD $1,250,000, and he is eligible for an annual base bonus of USD $4,530,442.00, reflecting his average bonus over the past five years, with actual amounts set each year by the committee and both salary and bonus adjusted annually for inflation. On retirement, disability, or termination without cause, he or his estate is entitled to a cash severance equal to three full calendar years of base salary and three full calendar years of base bonus, paid after execution of a release, and on retirement he will also serve as a consultant for at least 18 months while continuing to receive base salary. Severance is reduced in the event of termination for cause as described in the agreement.
Initial Form 3 filed for XBiotech Inc. (XBIT) by David Soffer, who identifies his relationship to the issuer as a director. The filing states that the reporting person does not beneficially own any securities of the issuer. The Form 3 is an initial Section 16 filing that discloses current ownership; in this case there are no non-derivative or derivative holdings reported.
Thomas Martin Kuendig, a director of XBiotech Inc. (XBIT), filed an initial Form 3 disclosing beneficial ownership of 300,000 shares of the issuer's common stock. The filing reports 200,000 shares held directly and two indirect holdings of 50,000 shares each attributed to his daughters, Stephanie Kuendig and Michelle Kuendig. The event requiring the statement is dated 08/29/2025 and the form is signed on 09/29/2025. No derivative securities are reported on this form.
Form 3 filed for XBiotech Inc. (XBIT) by Troy Tevi David, indicating his status as a director of the issuer. The filing states the date of the event requiring the statement as 08/29/2025 and discloses that no securities are beneficially owned by the reporting person at the time of filing. The form is signed and dated 09/29/2025.
FAQ
What is the current stock price of Xbiotech (XBIT)?
What is the market cap of Xbiotech (XBIT)?
